Loratadine and montelukast FDA Approval Status
FDA Approved: No
Generic name: loratadine and montelukast
Company: Schering-Plough/Merck Pharmaceuticals
Treatment for: Allergic Rhinitis
This medicine is a single tablet combination of the active ingredients in Claritin (loratadine) and Singulair (montelukast sodium), both of which are indicated for the relief of symptoms of allergic rhinitis.
In June 2008, Schering-Plough Corp. and Merck & Co., Inc. announced the withdrawal of the New Drug Application (NDA) for the loratadine/montelukast combination tablet. The companies also terminated the Schering-Plough/Merck Pharmaceuticals respiratory joint venture.
Development Timeline for loratadine and montelukast
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.